Michael Maldonado
Bristol-Myers Squibb Company
Michael A. Maldonado is the clinical development lead for abatacept in the Inflammation and Fibrosis Division of R&D at Bristol Myers Squibb in Lawrenceville New Jersey. He has a BSE in Bioengineering from the University of Pennsylvania and an MD from the University of Puerto Rico. He trained as a rheumatologist and immunologist at the University of North Carolina at Chapel Hill. He was an assistant professor of medicine at the University of Pennsylvania School of Medicine were his lab studied molecular mechanism of systemic autoimmunity. He joined Bristol Myers Squibb in 2006.
Appearances
DateFebruary 2, 2021From the onset of the COVID-19 pandemic, the extended medical community launched a broad effort to tackle this public health threat. Building on lessons from prior epidemics, including most recently AIDS, SARS, MERS and Ebola, this ranged from vaccine development to repurposing available therapies…Session Speaker
Bristol-Myers Squibb Company
DateFebruary 2, 2021Panelists
CDER, FDAHealth CanadaBiogenOmeros CorporationBristol-Myers Squibb CompanyMerck & Co., Inc.Speaker
